Published in Expert Rev Vaccines on June 20, 2016
An Atypical Local Vesicular Reaction to the Yellow Fever Vaccine. Vaccines (Basel) (2017) 0.75
Duration of antiviral immunity after smallpox vaccination. Nat Med (2003) 7.39
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol (2008) 7.18
Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med (2007) 6.13
Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol (2003) 5.51
Intussusception among infants given an oral rotavirus vaccine. N Engl J Med (2001) 5.33
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 5.22
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 4.23
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet (2001) 3.09
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ (1981) 2.36
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2010) 2.00
Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol (2009) 1.94
Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol (1998) 1.90
Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ (1962) 1.85
Vaccines and vaccination against yellow fever. WHO position paper -- June 2013. Wkly Epidemiol Rec (2013) 1.71
Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2000) 1.67
Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA (1996) 1.64
Adverse event reports following yellow fever vaccination. Vaccine (2008) 1.63
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine (2002) 1.53
Detection of yellow fever 17D genome in urine. J Clin Microbiol (2010) 1.52
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep (2002) 1.48
Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg (1963) 1.47
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine (2009) 1.36
Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics (2003) 1.36
Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol (1973) 1.35
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg (2002) 1.35
Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine (2005) 1.31
Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis (2002) 1.30
Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med (2007) 1.27
Development of a new hydrogen peroxide–based vaccine platform. Nat Med (2012) 1.24
Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med (1994) 1.23
Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health (1999) 1.22
Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol (2006) 1.21
Immunity to yellow fever nine years after vaccination with 17D vaccine. Trans R Soc Trop Med Hyg (1952) 1.20
Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep (1997) 1.19
Yellow fever. J Clin Virol (2014) 1.18
Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis (1994) 1.18
Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J (2001) 1.17
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine (2011) 1.15
An inactivated cell-culture vaccine against yellow fever. N Engl J Med (2011) 1.13
Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine (2010) 1.12
Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine (2011) 1.11
Viscerotropic disease following yellow fever vaccination in Peru. Vaccine (2009) 1.11
Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine (2006) 1.08
Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines (2012) 1.07
Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica (2004) 1.02
Wanted, dead or alive: new viral vaccines. Antiviral Res (2009) 1.02
The role of health economic analyses in vaccine decision making. Vaccine (2013) 1.02
Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg (2011) 1.01
Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine (2013) 1.01
Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal (2006) 1.01
Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis (2009) 0.97
Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine (2004) 0.95
Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA (1966) 0.93
Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods (2008) 0.92
Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics (2001) 0.92
Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol (2013) 0.92
Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine (2006) 0.92
Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol (1999) 0.90
Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol (2010) 0.90
Is it time for a new yellow fever vaccine? Vaccine (2010) 0.90
Yellow fever vaccine-associated adverse events following extensive immunization in Argentina. Vaccine (2014) 0.90
Low Thymic Activity and Dendritic Cell Numbers Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans. J Immunol (2015) 0.89
Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol (2013) 0.89
[Long term persistence of yellow fever neutralising antibodies in elderly persons]. Bull Soc Pathol Exot (2011) 0.89
Safety profile of the yellow fever vaccine Stamaril®: a 17-year review. Expert Rev Vaccines (2013) 0.88
How advances in immunology provide insight into improving vaccine efficacy. Vaccine (2014) 0.88
Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep (2015) 0.87
Duration of post-vaccination immunity against yellow fever in adults. Vaccine (2014) 0.86
Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg (2010) 0.86
Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil. Vaccine (2014) 0.86
Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine (2004) 0.86
The early cellular signatures of protective immunity induced by live viral vaccination. Eur J Immunol (2012) 0.86
Short report: Incidence of yellow fever vaccine-associated neurotropic disease. Am J Trop Med Hyg (2009) 0.85
[Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue]. Rev Salud Publica (Bogota) (2009) 0.85
Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci U S A (2015) 0.84
Vaccine-mediated immunity against dengue and the potential for long-term protection against disease. Front Immunol (2014) 0.83
A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res (2012) 0.83
Surveillance for adverse events following immunization (AEFI) in Switzerland--1991-2001. Vaccine (2010) 0.83
Traditional smallpox vaccination with reduced risk of inadvertent contact spread by administration of povidone iodine ointment. Vaccine (2007) 0.83
Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine (2011) 0.82
Demographic profile of sylvatic yellow fever in Brazil from 1973 to 2008. Trans R Soc Trop Med Hyg (2013) 0.82
Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines (2015) 0.81
Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine (2014) 0.81
Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine (2013) 0.81
Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics (2001) 0.81
Yellow fever revaccination guidelines change - a decision too feverish? Clin Microbiol Infect (2013) 0.80
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine (2015) 0.79
[Duration of immunity after yellow fever vaccination]. Ann Soc Belg Med Trop (1920) (1954) 0.79
Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Vaccine (2007) 0.78
Yellow fever vaccination: is one dose always enough? Travel Med Infect Dis (2013) 0.78
A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz (2015) 0.78
The US-Certified Yellow Fever Vaccination Center Registry: a tool for travelers, state health departments, and vaccine providers. J Travel Med (2006) 0.77
Deaths following vaccination: What does the evidence show? Vaccine (2015) 0.76
Serologic assessment of yellow fever immunity in the rural population of a yellow fever-endemic area in Central Brazil. Rev Soc Bras Med Trop (2013) 0.76
Lessons learned from making and implementing vaccine recommendations in the U.S. Vaccine (2015) 0.76
Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. Jpn J Infect Dis (2008) 0.76